Generation Bio Co. (NASDAQ:GBIO) Director Acquires $82,450.00 in Stock

Generation Bio Co. (NASDAQ:GBIO) Director Anthony G. Quinn purchased 85,000 shares of the stock in a transaction on Monday, January 13th. The stock was bought at an average cost of $0.97 per share, for a total transaction of $82,450.00. Following the completion of the acquisition, the director now owns 299,286 shares in the company, valued at approximately $290,307.42. This trade represents a 39.67 % increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink.

Generation Bio Stock Performance

NASDAQ:GBIO opened at $0.88 on Wednesday. Generation Bio Co. has a 52 week low of $0.75 and a 52 week high of $4.65. The firm’s 50-day simple moving average is $1.35 and its 200 day simple moving average is $2.13. The firm has a market cap of $58.78 million, a price-to-earnings ratio of -0.40 and a beta of 2.72.

Institutional Inflows and Outflows

Several hedge funds have recently made changes to their positions in the business. FMR LLC grew its position in Generation Bio by 0.3% during the third quarter. FMR LLC now owns 5,320,266 shares of the company’s stock worth $13,141,000 after buying an additional 15,656 shares in the last quarter. Baker BROS. Advisors LP raised its holdings in Generation Bio by 61.1% in the 3rd quarter. Baker BROS. Advisors LP now owns 1,944,945 shares of the company’s stock valued at $4,804,000 after acquiring an additional 737,988 shares in the last quarter. State Street Corp lifted its position in shares of Generation Bio by 1.2% during the 3rd quarter. State Street Corp now owns 992,188 shares of the company’s stock valued at $2,451,000 after acquiring an additional 11,669 shares during the period. Charles Schwab Investment Management Inc. grew its holdings in shares of Generation Bio by 2.1% during the 3rd quarter. Charles Schwab Investment Management Inc. now owns 423,299 shares of the company’s stock worth $1,046,000 after purchasing an additional 8,692 shares in the last quarter. Finally, Bank of New York Mellon Corp increased its position in shares of Generation Bio by 31.2% in the second quarter. Bank of New York Mellon Corp now owns 186,756 shares of the company’s stock worth $527,000 after purchasing an additional 44,378 shares during the period. 95.22% of the stock is owned by institutional investors.

Analyst Ratings Changes

A number of brokerages have recently weighed in on GBIO. Needham & Company LLC lowered their target price on Generation Bio from $10.00 to $8.00 and set a “buy” rating on the stock in a research note on Wednesday, January 8th. Wedbush reaffirmed an “outperform” rating and issued a $5.00 price objective on shares of Generation Bio in a report on Thursday, November 7th.

About Generation Bio

Generation Bio Co develops non-viral genetic medicines for the treatment of rare and prevalent diseases. The company develops cell-targeted lipid nanoparticle (ctLNP) platform, a modular delivery system for nucleic acids to avoid off-target clearance by the liver and spleen that enables ctLNPs to persist in systemic circulation, which allows for highly selective and potent ligand-driven targeting to specific tissues and cell types; and novel immune-quiet DNA (iqDNA) to enable long-lasting high levels of gene expression from non-integrating episomes and avoids innate immune sensors that have long prevented DNA from use in non-viral systems.